Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
The complex web of PARP inhibitor development
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
Tango faces a fresh PRMT5 competitor
New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.
Nothing like Hippo for cooling investor enthusiasm
Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.
Bristol puts Mirati out of its misery
The acquisition brings closure for Mirati at last, though some investors will feel disappointed.
Olema takes its antagonist/degrader concept into phase 3
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
